Uniting to end the TB epidemic: Advances in disease control from prevention to better diagnosis and treatment

BMC Medicine

Volumn 14, Issue 1, 2016, Pages

  Abubakar, Ibrahim ^a   Lipman, Marc ^a   McHugh, Timothy D ^a   Fletcher, Helen ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Elimination; Multi drug resistant tuberculosis; Tuberculosis

Indexed keywords

BCG VACCINE; MYCOBACTERIUM VACCINE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; BACTERIUM CULTURE; DISEASE TRANSMISSION; DNA FINGERPRINTING; DRUG EFFICACY; DRUG SENSITIVITY; EDITORIAL; EPIDEMIC; EXPERIMENTAL THERAPY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GENE SEQUENCE; GENOTYPE; GEOGRAPHIC INFORMATION SYSTEM; GLOBAL DISEASE BURDEN; HUMAN; MORBIDITY; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NEXT GENERATION SEQUENCING; PREDICTIVE VALUE; RELAPSE; SINGLE NUCLEOTIDE POLYMORPHISM; SMEAR; THORAX RADIOGRAPHY; TUBERCULOSIS; TUBERCULOSIS CONTROL; GENOMICS; GLOBAL HEALTH; MOLECULAR DIAGNOSIS; MULTIMODALITY CANCER THERAPY; TRENDS;

ANTITUBERCULAR AGENTS; COMBINED MODALITY THERAPY; GENOMICS; GLOBAL HEALTH; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; TUBERCULOSIS;

EID: 85007494468     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/s12916-016-0599-1     Document Type: Editorial

References (14)

1. WHO. Global tuberculosis report 2015 [Internet]. WHO. [cited 2016 Mar 9]. Available from: http://www.who.int/tb/publications/global_report/en/.
2. WHO. WHO End TB Strategy [Internet]. WHO. [cited 2014 Dec 20]. Available from: http://www.who.int/tb/post2015_strategy/en/.
3. Yates TA, Khan PY, Knight GM, Taylor JG, McHugh TD, Lipman M, et al. The transmission of Mycobacterium tuberculosis in high burden settings. Lancet Infect Dis. 2016;16(2):227-38.
4. Abubakar I, Lipman M, Anderson C, Davies P, Zumla A. Tuberculosis in the UK-time to regain control. BMJ. 2011;343:d4281.
5. Pareek M, C. Greenaway, Noori T, Munoz J, Zenner D. The impact of migration on tuberculosis epidemiology and control in high-income countries: a review. BMC Med. 2016. doi: 10.1186/s12916-016-0595-5.
6. Witney A, Cosgrove C, Arnold A, Hinds J, Stoker N, Butcher PD. Clinical use of Whole Genome Sequencing for Mycobacterium tuberculosis. BMC Med. 2016 doi: 10.1186/s12916-016-0598-2.
7. Hatherell H, Colijn C, Stagg HR, Jackson C, Winter J, Abubakar I. Interpreting whole genome sequencing for investigating tuberculosis transmission: a systematic review. BMC Med. 2016. doi: 10.1186/s12916-016-0566-x
8. McCreesh N, Looker C, Dodd PJ, Plumb I, Shanaube K, Muyoyeta M, et al. Comparison of indoor contact time data in Zambia and Western Cape, South Africa suggests targeting of interventions to reduce Mycobacterium tuberculosis transmission should be informed by local data. BMC Infect Dis. 2016;16:71.
9. Haas C, Roe J, Pollara G, Mehta M, Noursadeghi M. Diagnostic 'omics' for active tuberculosis. BMC Med. 2016. doi: 10.1186/s12916-016-0583-9.
10. Martin L, Roper M, Grandjean L, Gilman R, Coronel J, Caviedes L, et al. Rationing tests for drug-resistant tuberculosis-who are we prepared to miss? BMC Med. 2016. doi: 10.1186/s12916-016-0576-8.
11. Phelan J, Coll F, McNerney R, Ascher D, Pirez D, Furnham N, et al. Mycobacterium tuberculosis whole genome sequencing and protein structure modelling provides insights into anti-tuberculosis drug resistance. BMC Med. 2016. doi: 10.1186/s12916-016-0575-9.
12. Phillips PPJ, Mendel C, Burger D, Crook A, Nunn A, Dawson R, et al. Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials. BMC Med. 2016;14:19.
13. Ranzani O, Carvalho C, Waldman E, Rodrigues LC. The impact of being homeless on the unsuccessful outcome of treatment of pulmonary TB in S�o Paulo State, Brazil. BMC Med. 2016 Mar 23; doi: 10.1186/s12916-016-0584-8.
14. Phillips PPJ, Dooley KE, Gillespie SH, Heinrich N, Stout JE, Nahid P. A new trial design to accelerate tuberculosis drug development: The Phase 2C Selection Trial with Extended Post-treatment follow-up (STEP). BMC Med. 2016 doi: 10.1186/s12916-016-0597-3.